Table of Contents
NMN (Nicotinamide Mononucleotide) IV therapy has been shown to influence several biomarkers associated with aging, metabolism, and overall health.
Key Biomarkers Improved by NMN IV #
| Biomarker | Expected Change | Timeline | Clinical Significance |
|---|---|---|---|
| Intracellular NAD+ levels | +30–80% | Hours to days | Direct measure of therapy effectiveness |
| SIRT1/SIRT3 activity | Increased | Days to weeks | Longevity pathway activation |
| Oxidative stress markers (8-OHdG) | Decreased | 2–4 weeks | Reduced DNA damage |
| Insulin sensitivity (HOMA-IR) | Improved | 4–8 weeks | Better glucose metabolism |
| Mitochondrial biogenesis markers | Increased | 4–12 weeks | More efficient energy production |
| Telomere length | Preserved/Improved | Months | Cellular aging rate slowed |
| Inflammatory markers (CRP, IL-6) | Decreased | 2–6 weeks | Systemic inflammation reduced |
| HRV (Heart Rate Variability) | +15–25% | 2–4 weeks | Improved cardiovascular resilience |
The speed and extent of improvement depend on individual factors such as baseline health status, dosage, and frequency. While some changes like increased NAD+ levels and reduced oxidative stress may be rapid (within days to weeks), others such as telomere maintenance take longer (weeks to months).
To maximize benefits, NMN IV therapy should be complemented with personalized lifestyle interventions and ongoing monitoring of these biomarkers.
